Trials / Conditions / Recurrent Waldenstrom Macroglobulinemia

Recurrent Waldenstrom Macroglobulinemia

12 registered clinical trials studyying Recurrent Waldenstrom Macroglobulinemia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia NCT07420959	Mayo Clinic	Phase 1 / Phase 2
Recruiting	Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810	Mayo Clinic	Phase 1
Withdrawn	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683	Yazeed Sawalha	Phase 1
Terminated	Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinem NCT03506373	Mayo Clinic	Phase 2
Terminated	Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymph NCT03269552	University of Washington	Phase 2
Terminated	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906	Fred Hutchinson Cancer Center	Phase 2
Active Not Recruiting	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma NCT03147885	Barbara Ann Karmanos Cancer Institute	Phase 1 / Phase 2
Active Not Recruiting	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT03015896	David Bond, MD	Phase 1 / Phase 2
Completed	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220	Kami Maddocks	Phase 1
Completed	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980	Mayo Clinic	Phase 2
Completed	Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or R NCT01381692	National Cancer Institute (NCI)	Phase 1 / Phase 2
Terminated	Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia NCT01198067	M.D. Anderson Cancer Center	Phase 1